Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Hosted on MSN
D Boral Capital initiates coverage of Prelude Therapeutics (PRLD) with buy recommendation
Fintel reports that on May 4, 2026, D. Boral Capital initiated coverage of Prelude Therapeutics (NasdaqGS:PRLD) with a Buy recommendation. Analyst Price Forecast Suggests 32.84% Upside As of April 28, ...
Prelude Therapeutics ( (PRLD)) has issued an update. Prelude Therapeutics reported full-year 2025 financial results on March 10, 2026, and outlined a 2026 program roadmap centered on its JAK2V617F and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results